High prevalence of glaucoma, high risk of glaucoma among geriatric population coupled with globally aging population, and rising awareness among emerging economies and veterans as an effect of government efforts and awareness programs by NGOs are the major factors which are expected to fuel the glaucoma treatment drugs market globally.
Glaucoma being the second common cause of blindness has emerged as a worldwide problem. It was estimated that approximately 60 million people were affected with glaucoma worldwide in year 2013. The statistics clearly advocates the high demand for glaucoma treatment drugs across the globe. In the current scenario, drugs available in the market are not capable of treating the glaucoma from the roots. For the same reason, people tend to opt for substitutes which include surgery for glaucoma or laser treatment. Though these treatments cure the patient completely, they also tend to provide patients with harmful side effects and incurs high amount of currency. All these factors have encouraged many small players engaged in clinical stage activities to develop new glaucoma drugs for treatment of disease, many among them are expected to launch during the forecast period, 2016 - 2020.
The expected launch of Vasneo by Bausch & Lomb Incorporated in 2016 is expected to revolutionize the market, as the drug is expected to generate high amount of revenue in year 2017. It is anticipated that the drug would be used as a first-line therapy for the treatment of glaucoma. Strong efficacy and simplified therapeutic regiment agent presence in the drug would increase the use of drug. The launch of Vasneo is expected to further elevate the revenue share of prostaglandin analogue drug class. In 2018, market would be further augmented by the launch of another new drug class ROCK Inhibitor’s drug in the market. Roclatan, which is expected be launched in 2019 is also expected to provide successful glaucoma treatment option to the ophthalmologists, which in all would increase the total revenue generated from the market.
In 2015, on the basis of drug class, Prostaglandin analogs dominated the glaucoma treatment drugs market. The drugs belonging to prostaglandin analogs work by increasing the outflow of intraocular fluid from the eye. These drugs are usually taken as eye drops and preferred for people with open angle glaucoma. Beta blockers followed prostaglandin analogs in 2015. This drug class works by decreasing the production of intraocular fluid. These drugs are majorly available in generic form and are relatively inexpensive. This feature of beta blockers drug class makes it one of the preferred choices of drug in the emerging economies of Asia Pacific and Latin America region.
The report titled “Global Glaucoma Treatment Drugs Market Outlook to 2020 - New Product Launches Expected to Boost Market” provides a comprehensive analysis of the glaucoma treatment drugs market. The report includes the market share contributed by the sales of generic and patented drugs globally for treatment of glaucoma. Further, the market in the study is differentiated by various parameters such as drug classes which include prostaglandin analogues, alpha agonist, beta blockers, carbonic Anhydrase inhibitors, cholinergic, and combined medications. On the basis of formulation, glaucoma treatment drugs market is categorized into topical eye drops, semisolid dosage forms and pills. The market is also segmented by six geographical regions across the globe – North America, Europe, Asia Pacific, Middle East, Latin America, and Rest of the World. The stakeholders of this report includes the glaucoma treatment drugs market players, wholesalers, companies involved in research and development activities, and the new entrant who wish to invest in glaucoma treatment drugs market in future
For more coverage click on the link below: